An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins
Condition: Varicose Veins
MeSH terms: Varicose Veins
Intervention: Polidocanol Endovenous Microfoam 0.125%
Intervention description: Polidocanol Endovenous Microfoam 0.125%, single dose
Intervention MeSH terms: Polidocanol
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 16.0
Sex: All
Minimum age: 18 Years
Maximum age: 75 Years
Healthy volunteers: No
Keywords: Varicose Veins

Summary:

      To determine the effect and safety of Varisolve® 0.125% [0.2%]
    

Eligibility criteria:

        Inclusion Criteria:

          1. Male or female; age of consent to 75 years

          2. Baseline VEINES-Sym Questionnaire score less than 75 points

          3. Superficial venous disease manifested by both symptoms and visible varicosities

          4. Varicose vein clinical classification CEAP 2 through 5

          5. Incompetence of SFJ (reflux > 0.5 seconds on duplex ultrasonography) associated with
             incompetence of the great saphenous vein (GSV) or other major accessory vein

          6. Ability to comprehend and sign an informed consent document and complete study
             questionnaires in English

        Exclusion Criteria:

          1. Incompetence of the small saphenous vein (SSV)

          2. Ultrasonographic or other evidence of current or previous deep vein thrombosis,
             occlusion or incompetence

          3. Leg obesity impairing the ability to access the vein to be treated and/or to follow
             the post-procedural compression recommendations.

          4. Peripheral arterial disease in the leg to be treated contraindicating post-procedural
             compression.

          5. Reduced mobility (inability to maintain a brisk walk unaided for a minimum of 5
             minutes per hour per day).

          6. Planned prolonged automobile, bus, or air travel within 4 weeks following treatment,
             unless the patient can walk for at least 5 consecutive minutes every hour during
             travel.

          7. History of pulmonary embolism or stroke.

          8. Major surgery, prolonged hospitalization or pregnancy within 3 months of screening.

          9. Current anticoagulation therapy (within 7 days of enrollment).

         10. Participation in a clinical study involving an investigational pharmaceutical product
             or device within the 3 months prior to screening.

         11. Previous treatment in this study or in a previous Varisolve® study.

         12. Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic
             insufficiency; serious skin disease/condition that may compromise the ability of the
             patient to comply with the compression protocol, etc.) or clinically significant
             laboratory abnormalities.

         13. Known allergic response to polidocanol, or severe and multiple allergic reactions.

         14. Women of childbearing potential not using effective contraception for at least one
             month prior to study enrollment and/or unwilling to continue birth control until their
             last study visit.

         15. Pregnant or lactating women.

         16. Current alcohol or drug abuse.